Some Notable Properties of the Standard Oncology Phase I Design

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.19, Iss.3, 2009-05, pp. : 543-555

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Continual Reassessment Method vs. Traditional Empirically Based Design: Modifications Motivated by Phase I Trials in Pediatric Oncology by the Pediatric Brain Tumor Consortium

By Onar Arzu Kocak Mehmet Boyett James

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 437-455

Taylor & Francis Ltd

Access to resources Recommend Favorite

An Adaptive Design for Phase II Non-Oncology Dose Selection Clinical Trials

By Su Zheng

Clinical Drug Investigation, Vol. 30, Iss. 6, 2010-06 ,pp. : 397-403

Adis International

Access to resources Recommend Favorite

Phase I oncology trials: risks and benefits vary by trial type

Reactions Weekly, Vol. 1, Iss. 1042, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Phase I oncology trials: risks and benefits vary by trial type

Inpharma, Vol. 1, Iss. 1478, 2005-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 15, 2012-08 ,pp. : 1660-1664

Bentham Science Publishers

Access to resources Recommend Favorite